Cancer

Title
Randomized Frontline Therapy Advanced Classical Hodgkin Lymphoma With Adcetris plus Doxorubicin, Vinblastine and Dacarbazine (Arm A) Versus Treatment With Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (Arm B).
Trial Number
204866022013
Number of Participants
1,040
Principal Investigator
Eligibility

To be eligible for this study, participants must be at least 18 years old. Participants must be treatment-naïve, histologically confirmed HL with Ann Arbor Stage III or IV disease with bi-dimensional measurable disease and an ECOG performance status = 2.

Purpose

The main purpose of this study is to find out how well treatment with Arm A (adcetris, doxorubicin, vinblastine and dacarbazine) works compared to treatment with Arm B (doxorubicin, bleomycin, vinblastine and dacarbazine for advanced classical Hodgin lymphoma.

Enrollment

(708) 327-3228

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.